Why Jazz Pharmaceuticals stock is back in focus after mixed cancer updates

Jazz Pharmaceuticals (JAZZ) is back on investors’ radar after the company reported a phase 3 setback for Zepzelca in second-line small cell lung cancer and, in parallel, highlighted growth potential in its first-line maintenance indication.

At the same time, Jazz Pharmaceuticals announced a new collaboration with AbCellera to discover T cell engaging multispecific antibodies for gastrointestinal cancers and other solid tumors, adding another oncology program alongside its existing pipeline.

Despite a modest 1-day share price decline of 1.59% to US$226.20 and a 1-month share price return down 4.72%, Jazz Pharmaceuticals has a 90-day share price return of 23.82% and a 1-year total shareholder return of 110.40%. This helps explain why the recent Zepzelca setback and AbCellera collaboration are being viewed through a longer-term pipeline lens.

If Jazz Pharmaceuticals has you looking closer at cancer and biotech opportunities, it could be a good moment to broaden your watchlist with 38 healthcare AI stocks

With Jazz Pharmaceuticals shares up 23.82% over 90 days and 110.40% over the past year, yet trading below some published fair value models, the key question is whether investors are missing something or if the market is already pricing in future growth.

Most Popular Narrative: 12% Undervalued

Compared with Jazz Pharmaceuticals' last close at $226.20, the most widely followed narrative points to a fair value of $257.00, using a 7.55% discount rate to assess long term cash flows and earnings power.

The expected approval and launches of multiple therapies (dordaviprone for H3 K27M mutant diffuse glioma and Zepzelca in first line maintenance for small cell lung cancer) are set to drive new revenue streams and address unmet needs in rare cancers. This is described as supporting topline performance and more consistent earnings. Ongoing investments in R&D, commercialization infrastructure, and international launches are presented as lowering barriers to entry in new geographies as healthcare access expands. Within this narrative, these factors are seen as positioning Jazz for steady long term market presence and revenue generation.

Curious what earnings, revenue mix and profit margin profile would need to sit behind that $257.00 figure, and what timeline analysts are using to frame that scenario for Jazz Pharmaceuticals.

Result: Fair Value of $257.00 (UNDERVALUED)

However, that fair value story for Jazz Pharmaceuticals still leans heavily on a handful of cancer and neurology drugs, while patent pressure and new competitors could quickly challenge those assumptions.

Another View: What Jazz Pharmaceuticals’ P/S Ratio Is Telling You

The earlier fair value story for Jazz Pharmaceuticals leans heavily on long term cash flow assumptions, yet the current P/S ratio of 3.2x paints a different picture. It sits above peer average at 2.1x, but below the US Pharmaceuticals industry at 5.8x. The fair ratio estimate of 7.5x suggests there may be room for the market to shift. Is this a sign of extra risk being priced in, or an opportunity that is only partly recognised?

Next Steps

If the mixed sentiment on Jazz Pharmaceuticals has you torn, take a closer look at the underlying data now and weigh both sides of the story with 2 key rewards and 4 important warning signs

Looking for more investment ideas beyond Jazz Pharmaceuticals?

If Jazz Pharmaceuticals has sharpened your focus on opportunities, do not stop here. Use the Simply Wall St screener to identify other ideas that match your goals.

• Spot potential value opportunities early by scanning companies that currently screen as 44 high quality undervalued stocks and compare how their fundamentals stack up.
• Strengthen your capital preservation toolkit by reviewing 67 resilient stocks with low risk scores that pair resilient balance sheets with more measured risk profiles.
• Explore the screener containing 18 high quality undiscovered gems that combine solid fundamentals with relatively low market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.